Non-a non-b hepatitis surface antigen useful for the preparation of vaccines and methods of use
AssigneeInstitut Merieux
InventorChristian Trepo
Life of this patent
Estimating the term…
Abstract
A new vaccine against viral NANB hepatitis containing NANBs antigen in a physiologically acceptable medium. The vaccine is prepared by selecting serums or plasmas in which the presence of NANBs antigens has been identified and thereafter purifying the said antigens. Antibodies are also set forth.
Drawings
Claims9
A vaccine against viral NANB hepatitis comprising in a physiologically acceptable medium an amount of a purified non infectious fraction containing NANBs antigen in quantities sufficient to cause, on administration, an immunologic response, said NANBs antigen (1) having a density between 1.20 and 1.30 g/ml in a cesium chloride solution and between 1.15 and 1.25 g/ml in a sucrose solution (2) having an electrophoretic migration in the .alpha., .beta.-globulin zone;
- (3) being associated to particles with a viral appearance, spheres or filaments, the most typical of which have a size ranging from 10 to 45 nm in diameter, the complete virion appearing as a double envelope sphere of 35 to 45 nm;(4) when administered to a being having an immune system, said NANBs antigen causes the formation of antibodies with which it provides a precipitation reaction, the said antibodies also being capable of aggregating and/or precipitating the said viral particles including the complete double envelope virions containing a nucleocapside having a size of about 35-45nm, the said antibodies also being capable, when combined with a fluorescence agent, of causing a cytoplasmic and/or membranous fluorescence in liver tissue sections from subjects suffering from NANB hepatitis;
- the said antibodies being neither capable of aggregating the complete B hepatitis virus particles nor of causing a cytoplasmic and/or membranous fluorescence in the liver tissue of subjects suffering from B hepatitis.
A medicine for the prevention and treatment of viral NANB hepatitis comprising in a physiologically acceptable medium a purified gammaglobulin fraction containing anti-NANBs antibodies, the said anti-NANBs antibodies exhibiting principally the following characteristics:
- (1) they provide a precipitation reaction with NANBs antigens;
- (2) they are capable of aggregating and/or precipitating viral particles including complete double enveloped virions having a size of 35-45nm, associated to the NANBs antigen;
- (3) they are capable of causing, when combined with a fluorescence agent, a cytoplasmic and/or membranous fluorescence in liver tissue sections of subjects suffering from NANB hepatitis;
- and (4) the said antibodies are neither capable of aggregating or precipitating significantly complete particles of the B hepatitis virus nor of causing a cytoplasmic and/or membranous fluorescence in liver tissue of subjects suffering from B hepatitis.
A vaccination process against NANB hepatitis comprising administering to an animal having an immune system a purified NANBs antigen preparation containing said antigen in an amount sufficient to cause an immunologic response.
Dependencies are inferred from the claim text.